- All sections
- A - Human necessities
- A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
- A61P 5/48 - Drugs for disorders of the endocrine system of the pancreatic hormones
Patent holdings for IPC class A61P 5/48
Total number of patents in this class: 327
10-year publication summary
|
4
|
17
|
27
|
15
|
19
|
14
|
20
|
22
|
21
|
11
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Zealand Pharma A/S | 266 |
10 |
| Adocia | 145 |
9 |
| Novo Nordisk A/S | 2301 |
8 |
| Société des Produits Nestlé S.A. | 9941 |
6 |
| President and Fellows of Harvard College | 6040 |
6 |
| Seraxis, Inc. | 19 |
6 |
| Boehringer Ingelheim International GmbH | 4535 |
5 |
| DSM IP Assets B.V. | 5435 |
5 |
| Inserm (institut National de La Sante et de La Recherche Medicale) | 3339 |
5 |
| Vertex Pharmaceuticals Incorporated | 1602 |
4 |
| Icahn School of Medicine at Mount Sinai | 997 |
4 |
| Amgen Inc. | 4337 |
3 |
| Takeda Pharmaceutical Company Limited | 2719 |
3 |
| Camurus AB | 147 |
3 |
| Eli Lilly and Company | 4036 |
3 |
| MedImmune Limited | 612 |
3 |
| Shanghai Institute of Materia Medica, Chinese Academy of Sciences | 857 |
3 |
| Universidade Federal do Rio de Janeiro | 63 |
3 |
| University of Pittsburgh - Of the Commonwealth System of Higher Education | 3256 |
3 |
| Xuanzhu Pharma Co., Ltd. | 52 |
3 |
| Other owners | 232 |